🚀 VC round data is live in beta, check it out!
CytoSorbents Valuation Multiples
Discover revenue and EBITDA valuation multiples for CytoSorbents and similar public comparables like Pulsenmore, NeuroOne Medical, Implanet, Vivos and more.
CytoSorbents Overview
About CytoSorbents
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Founded
2014
HQ
Employees
149
Website
Financials (LTM)
EV
$61M
CytoSorbents Financials
CytoSorbents reported last 12-month revenue of $38M.
In the same LTM period, CytoSorbents generated $27M in gross profit and had net loss of ($9M).
Revenue (LTM)
CytoSorbents P&L
In the most recent fiscal year, CytoSorbents reported revenue of $37M and EBITDA of ($4M).
CytoSorbents expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $38M | XXX | $37M | XXX | XXX | XXX |
| Gross Profit | $27M | XXX | $26M | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($4M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (12%) | XXX | XXX | XXX |
| EBIT Margin | (36%) | XXX | (38%) | XXX | XXX | XXX |
| Net Profit | ($9M) | XXX | ($8M) | XXX | XXX | XXX |
| Net Margin | (24%) | XXX | (22%) | XXX | XXX | XXX |
| Net Debt | — | — | $10M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
CytoSorbents Stock Performance
CytoSorbents has current market cap of $38M, and enterprise value of $61M.
Market Cap Evolution
CytoSorbents' stock price is $0.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $61M | $38M | -4.9% | XXX | XXX | XXX | $-0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCytoSorbents Valuation Multiples
CytoSorbents trades at 1.6x EV/Revenue multiple, and (14.0x) EV/EBITDA.
EV / Revenue (LTM)
CytoSorbents Financial Valuation Multiples
As of April 11, 2026, CytoSorbents has market cap of $38M and EV of $61M.
Equity research analysts estimate CytoSorbents' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CytoSorbents has a P/E ratio of (4.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $38M | XXX | $38M | XXX | XXX | XXX |
| EV (current) | $61M | XXX | $61M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (14.0x) | XXX | XXX | XXX |
| EV/EBIT | (4.5x) | XXX | (4.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | 2.3x | XXX | XXX | XXX |
| P/E | (4.2x) | XXX | (4.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CytoSorbents Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
CytoSorbents Margins & Growth Rates
CytoSorbents' revenue in the last 12 month grew by 13%.
CytoSorbents' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
CytoSorbents Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (12%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (77%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 110% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
CytoSorbents Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pulsenmore | XXX | XXX | XXX | XXX | XXX | XXX |
| NeuroOne Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Implanet | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivos | XXX | XXX | XXX | XXX | XXX | XXX |
| Mauna Kea Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CytoSorbents M&A Activity
CytoSorbents acquired XXX companies to date.
Last acquisition by CytoSorbents was on XXXXXXXX, XXXXX. CytoSorbents acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by CytoSorbents
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCytoSorbents Investment Activity
CytoSorbents invested in XXX companies to date.
CytoSorbents made its latest investment on XXXXXXXX, XXXXX. CytoSorbents invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by CytoSorbents
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CytoSorbents
| When was CytoSorbents founded? | CytoSorbents was founded in 2014. |
| Where is CytoSorbents headquartered? | CytoSorbents is headquartered in United States. |
| How many employees does CytoSorbents have? | As of today, CytoSorbents has over 149 employees. |
| Who is the CEO of CytoSorbents? | CytoSorbents' CEO is Phillip P. Chan. |
| Is CytoSorbents publicly listed? | Yes, CytoSorbents is a public company listed on Nasdaq. |
| What is the stock symbol of CytoSorbents? | CytoSorbents trades under CTSO ticker. |
| When did CytoSorbents go public? | CytoSorbents went public in 2005. |
| Who are competitors of CytoSorbents? | CytoSorbents main competitors are Pulsenmore, NeuroOne Medical, Implanet, Vivos. |
| What is the current market cap of CytoSorbents? | CytoSorbents' current market cap is $38M. |
| What is the current revenue of CytoSorbents? | CytoSorbents' last 12 months revenue is $38M. |
| What is the current revenue growth of CytoSorbents? | CytoSorbents revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of CytoSorbents? | Current revenue multiple of CytoSorbents is 1.6x. |
| Is CytoSorbents profitable? | No, CytoSorbents is not profitable. |
| What is the current net income of CytoSorbents? | CytoSorbents' last 12 months net income is ($9M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.